Merakris Presents MTX-001 Biologic Drug at Innovations in Wound Healing Symposium
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 11 2025
0mins
Source: Globenewswire
- Scientific Exchange Platform: Merakris' Chief Scientific Officer, Dr. Roger Ilagan, has been invited to present at the Innovations in Wound Healing Symposium from December 11-14, 2025, sharing updates on MTX-001 to advance scientific dialogue in biologic drug development.
- Clinical Trial Progress: MTX-001, a first-in-class injectable biologic derived from cell-free amniotic fluid, is currently undergoing a multicenter Phase 2 trial (NCT04647240), with Part 1 completed and published in the International Wound Journal in March 2025, demonstrating promising safety and tolerability.
- Expanded Access Program: The therapy is available through an Expanded Access Program (EAP) for patients with cutaneous wounds, such as diabetic foot ulcers and pressure sores, reflecting Merakris' responsiveness to patient needs and market adaptability.
- Industry Leadership: Merakris is focused on developing biologically derived products to improve wound healing, showcasing its innovative leadership in regenerative medicine through advanced biologic manufacturing capabilities and a robust research pipeline.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like MRKR with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on MRKR
Wall Street analysts forecast MRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRKR is 9.00 USD with a low forecast of 8.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.630
Low
8.00
Averages
9.00
High
10.00
Current: 1.630
Low
8.00
Averages
9.00
High
10.00
About MRKR
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. The Company’s multi antigen recognizing (MAR)-T cell technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens, which are tumor targets, and kill tumor cells expressing those targets. These T cells are designed to recognize multiple tumor targets to produce broad-spectrum anti-tumor activity. It is developing two product candidates, including an Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601) and an Off-the-Shelf (OTS) product in various indications (MT-401-OTS). It has developed MT-601 to recognize multiple target antigens expressed by the tumor, thereby limiting tumor adaptation by negative antigen selection or downregulation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Continue Reading
Merakris Presents MTX-001 Biologic Drug at Innovations in Wound Healing Symposium
- Scientific Exchange Platform: Merakris' Chief Scientific Officer, Dr. Roger Ilagan, has been invited to present at the Innovations in Wound Healing Symposium from December 11-14, 2025, sharing updates on MTX-001 to advance scientific dialogue in biologic drug development.
- Clinical Trial Progress: MTX-001, a first-in-class injectable biologic derived from cell-free amniotic fluid, is currently undergoing a multicenter Phase 2 trial (NCT04647240), with Part 1 completed and published in the International Wound Journal in March 2025, demonstrating promising safety and tolerability.
- Expanded Access Program: The therapy is available through an Expanded Access Program (EAP) for patients with cutaneous wounds, such as diabetic foot ulcers and pressure sores, reflecting Merakris' responsiveness to patient needs and market adaptability.
- Industry Leadership: Merakris is focused on developing biologically derived products to improve wound healing, showcasing its innovative leadership in regenerative medicine through advanced biologic manufacturing capabilities and a robust research pipeline.
Continue Reading